GFAP and dementia: However, finger-prick DPS blood quantification of neurodegeneration markers has not been published in the setting of AD dementia or traumatic brain injury (TBI), or in any population using GFAP, which has distinct and clinically useful biological characteristics, such as a rapid response to neurological insults and shorter half-life.4 In this study, we aimed to compare gold-standard plasma quantification of NfL and GFAP with finger-prick DPS testing in patients with dementia, acute TBI and healthy volunteers.